Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple-Negative Breast Cancer.

Thorac Cancer · 2025 · PMC12052518 · PMID 40324951

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Of interest, further exploratory analysis for the COLET trial showed a trend toward improved ORR and PFS in PD‐L1 positive patients treated with cobimetinib + atezolizumab + paclitaxel/nab‐paclitaxel [ 60 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.